Bespak development contract award
Bespak’s Cambridge based Innovation Team have developed a novel, patented nasal drug delivery device, and the customer has contracted with Bespak to develop this for use in this specific application.
The contract win, the details of which are confidential, adds to Consort Medical’s Development pipeline, as programme NAS030. The programme may include drug handling.
Jonathan Glenn, Consort Medical Chief Executive commented: “We are delighted to have secured this contract in an exciting therapeutic area, and are pleased with the latest success of our Innovation team which was created approximately three years ago. The programme award represents the continued execution of our organic diversified growth strategy, further broadening the portfolio.”
Consort Medical will publish its Annual report on 25 July 2013, ahead of its AGM on 2 September 2013. Consort’s Q1 IMS will be released on 2 September 2013.
Consort – Tel: +44 1442 867920
Jonathan Glenn – Chief Executive
Richard Cotton – Finance Director
Brunswick Group – Tel: +44 20 7404 5959